PDK4 and diffuse large B-cell lymphoma: To prove the efficacy of the exosome-based nanomedicine in a DLBCL-resistant tumor model, results indicated that aCD20@ExoCTX/siPDK4 effectively downregulated PDK4 gene expression in vivo, enhancing the antitumor activity of rituximab and thereby inhibiting the generation of DLBCL tumor cells.